1. Introduction {#sec1-marinedrugs-17-00277}
===============

Angucyclines and their aglucones (angucyclinones) are a class of natural products containing an angularly assembled tetracyclic scaffold or a corresponding rearranged frame in the structure. They are the largest family of polycyclic aromatic polyketides produced by Gram-positive actinomycetes \[[@B1-marinedrugs-17-00277]\]. Since the first member of the class, tetrangomycin, was identified from *Streptomyces rimosus* in 1965 \[[@B1-marinedrugs-17-00277]\], dozens of angucyclines and angucyclinones have been found to display prominent cytotoxic and anti-proliferative properties \[[@B2-marinedrugs-17-00277],[@B3-marinedrugs-17-00277],[@B4-marinedrugs-17-00277]\]. Although their severe in vivo toxicity and limited water-solubility restricted their clinical application, this class of natural products still continuously draws attention due to their structural diversity and anti-neoplastic potential \[[@B5-marinedrugs-17-00277],[@B6-marinedrugs-17-00277],[@B7-marinedrugs-17-00277],[@B8-marinedrugs-17-00277]\]. To date, several subclasses of angucycline derivatives have been extensively investigated regarding their in vitro and in vivo anti-tumor effects. For instance, landomycin E displayed promising anti-cancer activity against multidrug-resistant cancer cells and induced apoptotic cell death as a consequence of rapid mitochondrial damage \[[@B9-marinedrugs-17-00277]\]. Further investigation indicated that rapid H~2~O~2~ generation and complex caspase activation contribute to its anti-neoplastic effects \[[@B10-marinedrugs-17-00277]\]. Jadomycins are atypical angucyclinones containing nitrogenous heterocycles in their structure, and jadomycins B and F were reported to induce DNA cleavage through the generation of cytosolic superoxide or the inhibition of type II topoisomerases, leading to the death of multidrug-resistant breast cancer cells \[[@B11-marinedrugs-17-00277],[@B12-marinedrugs-17-00277]\]. Lomaiviticins were first isolated from *Micromonospora lomaivitiensis* as dimers of kinamycin angucyclines with two diazofluorene functional groups \[[@B3-marinedrugs-17-00277]\]. One of them, lomaiviticin A, exhibited remarkable cytotoxicity against a panel of human cancer cells at nanomolar--picomolar concentrations by inducing double-strand breaks in DNA, and it is currently under preclinical evaluation \[[@B13-marinedrugs-17-00277],[@B14-marinedrugs-17-00277],[@B15-marinedrugs-17-00277]\]. Accordingly, angucyclines are still considered as promising candidates for anti-tumor drug development.

Angucyclines were mainly separated from terrestrial actinomycetes, though in recent years an increasing number of them have been identified from marine actinomycetes associated with seafloor sediments \[[@B4-marinedrugs-17-00277],[@B8-marinedrugs-17-00277],[@B16-marinedrugs-17-00277],[@B17-marinedrugs-17-00277],[@B18-marinedrugs-17-00277],[@B19-marinedrugs-17-00277]\], sponges \[[@B7-marinedrugs-17-00277]\], and mangrove forests \[[@B20-marinedrugs-17-00277]\]. We also initiated a screening for angucycline-producing strains employing PCR amplification of the β-ketoacyl synthase (KSα) gene from marine actinomycetes, and a *Streptomyces* sp. designated as OC1610.4 was obtained from the intertidal sediments. Its 16S rRNA nucleotide sequence (GenBank number: MK045847) is similar to those of *Streptomyces chromofuscus* (FJ486284) and *Streptomyces lannensis* (KM370050), with 81.8% and 81.6% similarity, respectively ([Supplementary Figure S1](#app1-marinedrugs-17-00277){ref-type="app"}). After this strain was cultured in Morel & Wetmore Modification medium (S-medium), four angucycline glycosides were identified, and one of the isolates, saquayamycin B, displayed potent cytotoxicity on human hepatoma carcinoma cells \[[@B21-marinedrugs-17-00277]\]. For the purpose of discovering more diversified analogues with cytotoxicity, three kinds of medium---Gauze's synthetic solid medium (GAU), yeast extract--malt extract starch medium (YMS), and yeast extract--malt extract agar medium (YMEA)---were further employed to reculture this strain. Thin-layer chromatography (TLC) profiles showed that more yellow spots displaying orange fluorescence under UV 365 nm light were observed in the EtOAc extract of GAU. Large-scale fermentation using GAU and isolation resulted in the identification of another seven angucyclines including two new derivatives. This paper reports their structure identification and cytotoxic, anti-migration, and anti-invasion activities on breast cancer cells of angucyclines obtained from *Streptomyces* sp. OC1610.4.

2. Results and Discussion {#sec2-marinedrugs-17-00277}
=========================

The strain *Streptomyces* sp. OC1610.4 was previously shaking-cultured in liquid S-medium (10 g/L glucose, 4 g/L yeast extract, 4 g/L K~2~HPO~4~, 2 g/L KH~2~PO~4~, 0.5 g/L MgSO~4~·7H~2~O, and 3.0% sea salt), and four angucycline glycosides---vineomycin D (**6**), saquayamycin B (**9**), landomycin N (**10**), and galtamycin C (**11**)---were characterized from the fermentation broth \[[@B21-marinedrugs-17-00277]\]. After being recultured in solid GAU (20 g/L amylogen, 1 g/L KNO~3~, 0.5 g/L NaCl, 0.5 g/L K~2~HPO~4~·H~2~O, 0.5 g/L MgSO~4~·H~2~O, and 0.01 g/L FeSO~4~·H~2~O), two new rearranged angucyline glycosides, vineomycins E and F (**1** and **2**), along with five known homologues, grincamycin L (**3**) \[[@B19-marinedrugs-17-00277]\], vineomycinone B~2~ (**4**) \[[@B22-marinedrugs-17-00277]\], fridamycin D (**5**) \[[@B23-marinedrugs-17-00277]\], moromycin B (**7**) \[[@B24-marinedrugs-17-00277]\], and saquayamycin B~1~ (**8**) \[[@B6-marinedrugs-17-00277],[@B25-marinedrugs-17-00277]\], were identified ([Figure 1](#marinedrugs-17-00277-f001){ref-type="fig"}).

Vineomycin E (**1**) was isolated as a trace constituent. Its molecular formula (C~31~H~34~O~12~) was determined by the *m/z* 599.2122 (\[M + H\]^+^, calc.d for C~31~H~3~5O~12~, 599.2129) from high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). The ^1^H NMR of **1** showed the signals of two pairs of ortho-coupled aromatic protons at δ~H~ 7.68 (m, H-6) and 7.70 (m, H-5), and δ~H~ 7.72 (d, J = 7.3 Hz, H-11) and 7.84 (d, J = 7.3 Hz, H-10), characteristic of rearranged tricyclic angucyclines, e.g., grincamycin L (**3**) \[[@B19-marinedrugs-17-00277]\], vineomycinone B~2~ (**4**) \[[@B22-marinedrugs-17-00277]\], and fridamycin D (**5**) \[[@B23-marinedrugs-17-00277]\]. The oxygenated methine proton signals at δ~H~ 4.92 (brd, *J* = 11.4 Hz, H-1A) and 4.97 (brs, H-1B), corresponding carbon signals at δ~C~ 72.2 (C-1A) and 91.0 (C-1B) ppm assigned by HMQC correlations, along with the two doublets of methyl groups at δ~H~ 1.26 (d, *J* = 6.9 Hz, H-6B) and 1.31 (d, *J* = 5.8 Hz, H-6A), implied the presence of two deoxy sugars, one of which formed a C-glycoside due to its anomeric carbon resonating at δ~H~ 72.2 \[[@B1-marinedrugs-17-00277]\]. The ^13^C NMR signals of **1** were very similar to those of fridamycin D (**5**) \[[@B23-marinedrugs-17-00277]\], except for the presence of a signal at δ~C~ 64.1 (C-4B) and the absence of a signal above δ~C~ 200, which indicated that **1** and fridamycin D (**5**) differed in the deoxy sugars. In the HMBC spectrum of **1**, the correlations from H-5 (δ~H~ 7.70) to C-6a (δ~C~ 132.9) and C-12b (δ~C~ 162.4); H-6 (δ~H~ 7.68) to C-7 (δ~C~ 189.2), C-12a (δ~C~ 116.6) and C-4a (δ~C~ 136.3); H-10 (δ~H~ 7.84) to C-8 (δ~C~ 159.7) and C-11a (δ~C~ 133.3); and H-11 (δ~H~ 7.72) to C-7a (δ~C~ 116.6), C-9 (δ~C~ 139.2), and C-12 (δ~C~ 189.3) supported the anthraquinone skeleton and the two hydroxyl groups at C-9 and C-12b ([Figure 2](#marinedrugs-17-00277-f002){ref-type="fig"}). The side chain and its location at C-4a were deduced by the HMBC correlations from H-13 (δ~H~ 1.27) to C-2 (δ~C~ 46.7), C-3 (δ~C~ 73.0) and C-4 (δ~C~ 41.2); H-2 (δ~H~ 2.48, 2.51) to C-1 (δ~C~ 176.4) and C-4 (δ~C~ 41.2); and H-4 (δ~H~ 3.00, 3.09) to C-4a (δ**~C~** 136.3), C-5 (δ~C~ 140.8), and C-12b (δ~C~ 162.4). Tricyclic angucyclines are generally derived from typical angucyclines with the same tetracyclic core structure under acidic conditions \[[@B1-marinedrugs-17-00277]\]; therefore, the absolute configuration of C-3 is proposed to be the same as that of saquayamycin B (**9**) and other tricyclic angucyclines, e.g., grincamycin L (**3**) and grincamycin B \[[@B19-marinedrugs-17-00277],[@B26-marinedrugs-17-00277]\]. The two deoxy sugars were deduced to be D-olivose and 4-dihydro-[l]{.smallcaps}-cinerulose B by the COSY correlations from H-1A (*δ*~H~ 4.92) through H-6A (*δ*~H~ 1.31), and correlations from H-1B (*δ*~H~ 4.97) through H-6B (*δ*~H~ 1.26) ([Figure 2](#marinedrugs-17-00277-f002){ref-type="fig"}). The HMBC correlations from H-1B (*δ*~H~ 4.97) to C-4A (*δ*~C~ 75.1), and H-2B (*δ*~H~ 3.88) to C-3A (*δ*~C~ 78.0) suggested that they constitute a 4-dihydro-[l]{.smallcaps}-cinerulose B-(1→4,2→3)-olivosyl group ([Figure 2](#marinedrugs-17-00277-f002){ref-type="fig"}). The NOESY correlations of H-1/H-3A,5A and H4A/H-6A confirmed the relative configurations of the *β*-D-olivosyl group ([Figure 2](#marinedrugs-17-00277-f002){ref-type="fig"}). The simultaneously appearing NOESY correlations H-3A/H-1B and H-3A/H-2B suggested that H-1B and H-2B are located in the axial and equatorial directions, respectively. The hydroxyl group at C-4B in the 4-dihydro-α-L-cinerulose B moiety was assigned in the axial direction by the NOESY correlation H-6B/H-4B. Thus, the structure of **1** was established and named vineomycin E (**1**). Deoxy sugar 4-dihydro-L-cinerulose B rarely occurred in the structure of an angucycline, and only one example, namely PI-083, has been reported to comprise a 4-dihydro-L-cinerulose B group to date \[[@B27-marinedrugs-17-00277]\].

Vineomycin F (**2**) was isolated as a yellow solid and has the molecular formula C~31~H~32~O~14~, determined by the *m/z* 629.1867 (\[M + H\]^+^, calc.d for C~31~H~33~O~14~, 629.1870) from HR-ESI-MS. The ^1^H NMR spectrum of **2** displayed the resonances of four aromatic protons and a set of aliphatic protons, similar to those of **1**. The prominent difference is that the anomeric proton signal of the terminal deoxy sugar in **2**, whose corresponding carbon resonated at δ~C~ 90.5 assigned by the HMQC spectrum, shifted to downfield *δ*~H~ 6.06 (H-1B). The ^13^C NMR spectrum of **2** showed 31 carbon signals in which δ~C~ 169.8, 171.4, and 173.8 were assigned to three carboxyl or ester carbonyl carbons. The chemical shift of the methyl group at *δ*~H~ 2.17 (s, H-6B) and the HMBC correlation from this signal to carbon at *δ*~H~ 169.8 (C-5B) supported the presence of an acetyl group ([Figure 3](#marinedrugs-17-00277-f003){ref-type="fig"}). After the signals of protons and carbons in **2** were completely assigned by HMQC and COSY spectra ([Table 1](#marinedrugs-17-00277-t001){ref-type="table"}), the structure of aglycone was established to be identical to that of **1** by the HMBC correlations associated with the four aromatic protons (*δ*~H~ 7.78, 7.84, 7.85, and 7.96) and the methane protons (*δ*~H~ 2.56, 2.59, and 3.10) ([Figure 3](#marinedrugs-17-00277-f003){ref-type="fig"}). The presence of the D-olivose moiety, including its configurations, was confirmed by the COSY correlations from H-1A (δ~H~ 5.03, d, *J* = 9.1 Hz) through H-6A (*δ*~H~ 1.26, d *J* = 5.6 Hz) and the NOESY correlations H-1/H-3A,5A and H4A/H-6A. The HMBC correlations from H-1A (*δ*~H~ 5.03) to C-8 (δ~C~ 159.6), C-9 (δ~C~ 138.8), and C-10 (δ~C~ 134.2) indicated the attachment of *β*-D-olivose at C-8 to form a C-glycoside ([Figure 3](#marinedrugs-17-00277-f003){ref-type="fig"}). The COSY correlations from H-1B (*δ*~H~ 6.06) through H-3B (*δ*~H~ 2.54), together with the HMBC correlations from H-2B (*δ*~H~ 4.34) to the carboxyl carbon at *δ*~H~ 171.4 (C-4B), suggested that the terminal sugar is a butyrate acid derivative. In addition, it linked with *β*-D-olivose through two ether bonds, which were deduced by the HMBC correlations from H-1B (δ~H~ 6.06) to C-4A (*δ*~C~ 75.3) and H-2B (δ~H~ 4.34) to C-3A (*δ*~C~ 74.6). The downfield shift of H-1B to δ~H~ 6.06 and the HMBC correlation from H-1B to the carbonyl carbon at *δ*~C~ 169.8 (C-5B) implied that the acetyl group attached at C-1B. The acetyl group and the butyrate acid derivative were probably the results of an oxidative break of the C--C bond between C-4 and C-5 in L-cinerulose B ([Figure 3](#marinedrugs-17-00277-f003){ref-type="fig"}).

Breast cancer is among the most common types of cancer affecting women worldwide and is the leading cause of cancer death in women \[[@B28-marinedrugs-17-00277]\]. The migration and invasion of breast cancer cells allow the cells to enter lymphatic vessels or the bloodstream and lead to cancer deterioration, relapse, difficult eradication, and even incurability \[[@B29-marinedrugs-17-00277]\]. Several investigations have reported that some angucyclines, such as jadomycins B, S, and F, are capable of inducing apoptosis in drug-resistant breast cancer cells \[[@B11-marinedrugs-17-00277],[@B12-marinedrugs-17-00277]\]. Moromycin B (**7**) was also reported to show significant cytotoxicity against MCF-7 human breast cancer cells, with a GI~50~ value of 5.6 μM \[[@B24-marinedrugs-17-00277]\]. Thus, we evaluated the cytotoxic activity of isolated angucyclines on the MCF-7, MDA-MB-231, and BT-474 cell lines employing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method ([Table 2](#marinedrugs-17-00277-t002){ref-type="table"}). Among the tested compounds, moromycin B (**7**), saquayamycin B~1~ (**8**), and saquayamycin B (**9**) displayed remarkable cytotoxicity against breast cancer cells, with IC~50~ values ranging from 0.16 to 0.67 μM. Vineomycin E (**1**) and fridamycin D (**5**) displayed medium cytotoxicity on the tested cells. After treatment of the aggressive triple-negative cell line MDA-MB-231 with saquayamycin B (**9**) at concentrations of 25 and 50 nM for 12 h, the invasion and migration capabilities of MDA-MB-231 cells were found to be depressed by Transwell and wound-healing assays ([Figure 4](#marinedrugs-17-00277-f004){ref-type="fig"}).

3. Materials and Methods {#sec3-marinedrugs-17-00277}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00277}
------------------------------------

Silica gel (200--300 mesh), used in column chromatography (CC), and silica gel GF~254~ (10--40 µm), used in thin layer chromatography (TLC), were purchased from Qingdao Marine Chemical Factory in China. Optical rotations were recorded with an Anton Paar MCP 200 polarimeter with a sodium lamp (589 nm) (Anton Paar GmbH, Graz, Austria). UV spectra were measured on a Genesys 10S UV-Vis spectrometer (Thermo Fisher Scientific Ltd., Waltham, MA, USA); IR spectra were recorded with a Nicolet IS5 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA); 1D and 2D NMR spectra were recorded on a Bruker AVANCE III 500 spectrometer (Bruker Inc., Karlsruhe, Germany). HPLC-HR-ESI-MS was performed on an Agilent 1200HPLC/6520QTOFMS (Agilent Technologies Inc., Santa Clara, CA, USA). Semipreparative HPLC isolation was conducted on an Agilent 1260 Infinity II (Agilent Technologies Inc., Santa Clara, CA, USA) with an ODS column (10 × 250 mm, YMC-Triart C18, YMC Co. Ltd., Tokyo, Japan).

3.2. Actinomycetes Strain {#sec3dot2-marinedrugs-17-00277}
-------------------------

The strain OC1610.4 was obtained from intertidal sediment using the method reported in our previous research \[[@B19-marinedrugs-17-00277]\]. DNA extraction and PCR amplification of 16S rRNA were conducted according to the instructions of the DNA isolation kit and PCR kit supplied by Shanghai Sangon Biotech Co., China, and 16S rRNA was sequenced by the same company. The 16S rRNA sequence was deposited at GenBank (accession no. MK045847), and the closely related taxa were retrieved from GenBank using BLAST software. The voucher strain (no. OC1610.4) was deposited at the Laboratory of Natural Products Chemistry, College of Marine Science, Shandong University at Weihai.

3.3. Fermentation, Extraction, and Isolation {#sec3dot3-marinedrugs-17-00277}
--------------------------------------------

The strain OC1610.4 was first picked out from the deposit tube and inoculated in 3 Erlenmeyer flasks (500 mL), each of which contained 100 mL GAU. After being shaking-cultured at 140 rpm, at 28 °C for 3 days, the spore and mycelia suspension was plated on Petri dishes containing 40 L GAU (20--30 mL/dish) and cultured for 9 days at 32 °C. The fermentation medium was sheared to pieces (\<2 × 2 cm) and extracted with EtOAc 4 times to give 8.6 g crude extract. The extract was subjected to silica gel CC (260 g, 200--300 mesh) eluting with *n*-hexane-acetone (10:1, 5:1, 2:1 and acetone). According to the TLC spots displaying orange fluorescence under UV 365 nm light, one fraction (F~1~) was obtained from the n-hexane-acetone (5:1) eluent, and 4 fractions (F~2a~--F~2d~) were obtained from the *n*-hexane-acetone (2:1) eluent. Fraction F~1~ (320 mg) was purified by semipreparative HPLC eluting with H~2~O (0.1% CH~3~CO~2~H)-CH~3~OH (80:20, *v/v*) to give 3-(3-hydroxy-phenyl)-propionic acid (5.6 mg, 14.2 min). Fraction F~2~a (267 mg) was isolated by semipreparative HPLC eluting with H~2~O (0.1% CH~3~CO~2~H)-CH~3~OH (80:20, *v/v*) to give **7** (3 mg, *t*~R~ 34.0 min) and **5** (9 mg, *t*~R~ 30.8 min). Fraction F~2b~ (175 mg) was isolated by semipreparative HPLC eluting with H~2~O (0.1% CH~3~CO~2~H)-CH~3~OH (80:20, *v/v*) to give **8** (4 mg, *t*~R~ 24.5 min). Fraction F~2c~ (109 mg) was isolated by semipreparative HPLC eluting with H~2~O (0.1% CH~3~CO~2~H)-CH~3~OH (83:17, *v/v*) to give **2** (8 mg, *t*~R~ 14.5 min), **1** (2 mg, *t*~R~ 16.7 min), and **3** (2 mg, *t*~R~ 18.2 min). F~2d~ (119 mg) was purified by semipreparative HPLC eluting with H~2~O (0.1% CH~3~CO~2~H)-CH~3~OH (67:33, *v/v*) to give **4** (9 mg, *t*~R~ 45.6 min).

*Vineomycin E* (**1**): yellow amorphous powder; $\left\lbrack \alpha \right\rbrack_{25}^{D}$ +28.4 (*c* 0.20, CH~2~Cl~2~); UV (MeOH) λ~max~ (log ε) 229 (3.53), 257 (3.37), 294 (2.97) nm; IR (neat) *ν*~max~ 3402, 2977, 2928, 2853, 1719, 1631, 1435, 1373, 1259, 1073, 767, 751 cm^--1^; ^1^H NMR (500 MHz, CD~3~OD) and ^13^C NMR (125 MHz, CD~3~OD) data, see [Table 1](#marinedrugs-17-00277-t001){ref-type="table"}; HR-ESI-MS *m/z* 599.2122 (\[M + H\]^+^, calc.d for C~31~H~35~O~12~, 599.2129).

*Vineomycin F* (**2**): yellow amorphous powder; $\left\lbrack \alpha \right\rbrack_{25}^{D}$ +23.2 (*c* 0.50, CH~2~Cl~2~); UV (MeOH) λ~max~ (log ε) 229 (3.11), 257 (2.95), 294 (2.55) nm; IR (neat) *ν*~max~ 3393, 2966, 2927, 2855, 1717, 1627, 1607, 1433, 1369, 1260, 1074, 950, 798 cm^--1^; ^1^H NMR (500 MHz, acetone-d~6~) and ^13^C NMR (125 MHz, acetone-d~6~) data, see [Table 1](#marinedrugs-17-00277-t001){ref-type="table"}; HR-ESI-MS *m/z* 629.1867 (\[M + H\]^+^, calc.d for C~31~H~33~O~14~, 629.1870).

3.4. Cell Culture {#sec3dot4-marinedrugs-17-00277}
-----------------

Human breast cancer cells MCF-7, MDA-MB-231, and BT-474 were bought from the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, China. The cell lines were cultured in RPMI-1640 medium (Hyclone) containing 10% fetal bovine serum (FBS) supplemented with 100 units/mL of penicillin and 100 μg/mL of streptomycin. All cells were incubated in 5% CO~2~ at 37 °C.

3.5. MTT Assay {#sec3dot5-marinedrugs-17-00277}
--------------

The cytotoxic activity of compounds **1**--**11** against breast cancer cells MCF-7, MDA-MB-231, and BT-474 was determined using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described in our previous research \[[@B30-marinedrugs-17-00277]\]. Doxorubicin was used as a positive control drug and deionized H~2~O with the same DMSO concentration was used as a parallel control.

3.6. Wound-Healing Assay {#sec3dot6-marinedrugs-17-00277}
------------------------

The anti-migration effect of saquayamycin B (**9**) against breast cancer cells MDA-MB-231 was evaluated using a wound-healing assay \[[@B31-marinedrugs-17-00277]\]. Briefly, MDA-MB-231 cells were cultured in a 24-well plate at a concentration of 5 × 10^5^ cells/mL with RPMI-1640 (10% FBS). When the cell density grew to 90%, linear gaps were scratched by micropipette tips, and the suspension cells were flushed out using phosphate-buffered saline (PBS). Then, the cells in the plate were starved for 12 h to eliminate the interference of proliferation. Wound healing rate (%) = \[1 -- (scratch width of saquayamycin B-treated group/scratch width of control group)\] × 100%.

3.7. Transwell Assay {#sec3dot7-marinedrugs-17-00277}
--------------------

A Transwell assay was employed to evaluate the invasion capacity of MDA-MB-231 cells \[[@B29-marinedrugs-17-00277]\]. A mixture of Matrigel and serum-free RPMI-1640 (1:8) was precoated on the upper chamber membrane of the filter insert. Then, 200 μL cell suspension (5 × 10^5^ cells/mL) in serum-free RPMI-1640 was poured into the upper chamber and treated with 25 and 50 nM saquayamycin B or DMSO for 12 h. RPMI-1640 medium containing 20% FBS was filled in the lower chamber as a chemoattractant. The invading cells in the lower chamber were fixed with methanol for 15 min and stained by 0.5% cresyl violet, followed by washing 3 times with double-distilled water and air drying. Three random views were photographed, and the invasive cells were counted under a Nikon TE2000 microscope with NIS elements viewer 4.2.0 software (Nikon Instech Co., Ltd., Tokyo, Japan).

4. Conclusions {#sec4-marinedrugs-17-00277}
==============

In total, 11 angucycline glycosides, including two new compounds, vineomycin E (**1**) and vineomycin F (**2**), were identified from the fermentation medium of marine-derived *Streptomyces* sp. OC1610.4. Among the isolated angucycline glycosides, vineomycin E (**1**) contains a rarely occurring deoxy sugar, 4-dihydro-[l]{.smallcaps}-cinerulose, and vineomycin F (**2**) contains an unusual ring-cleavage deoxy sugar. Moromycin B (**7**), saquayamycin B~1~ (**8**), and saquayamycin B (**9**) displayed potent cytotoxic activity against breast cancer cells MCF-7, MDA-MB-231, and BT-474, with IC~50~ values ranging from 0.16 to 0.67 μM. Saquayamycin B (**9**) inhibited the migration and invasion of MDA-MB-231 cells in a dose-dependent manner.

The following are available online at <https://www.mdpi.com/1660-3397/17/5/277/s1>. This section includes the colonial morphology, 16S rRNA gene sequences data and phylogenetic analysis of *Streptomyces* sp. N1510.2, and the HR-ESI-MS, 1D and 2D NMR spectra for **1**--**2**.
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![COSY, HMBC, and key NOESY correlations for **2**.](marinedrugs-17-00277-g003){#marinedrugs-17-00277-f003}

![Saquayamycin B (**9**) treatment dose-dependently inhibited invasion and migration in the breast cancer cell line MDA-MB-231. Cell invasion and migration were observed with incubation for 12 h by Transwell and wound-healing assays. **A**: cresyl violet staining in the Transwell assay, captured by a microscope (100× magnification). **B**: quantification by counting the number of cells in the Transwell assay. **C**: effects of wound-healing captured by a microscope (100× magnification). **D**: analysis of the wound-healing rate. Results are presented as mean ± SD. \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 compared to the control group.](marinedrugs-17-00277-g004){#marinedrugs-17-00277-f004}
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###### 

^1^H and ^13^C NMR data of **1** and **2** (500 MHz and 125 MHz) ^a^.

  ----------------------------------------------------------------------------------------------------
  No.                                  1 ^b^     2 ^c^                           
  ------------------------------------ --------- --------------------- --------- ---------------------
  1                                    176.4 s   \-                    173.8 s   \-

  2                                    46.7 t    2.48, d (15.5)\       45.5 t    2.56, d (15.2)\
                                                 2.51, d (15.5)                  2.59, d (15.2)

  3                                    73.0 s    \-                    72.1 s    \-

  4                                    41.2 t    3.01, d (13.1)\       40.8 t    3.10, brs
                                                 3.08, d (13.1)                  

  4a                                   136.3 s   \-                    136.2 s   \-

  5                                    140.8 d   7.70, m^c^            140.8     7.85, d (5.6)

  6                                    119.6 d   7.68, m^c^            119.3 d   7.78, d (5.6)

  6a                                   132.9 s   \-                    132.5 s   \-

  7                                    189.2 s   \-                    189.1 s   \-

  7a                                   116.6 s   \-                    116.3 s   \-

  8                                    159.7 s   \-                    159.6 s   \-

  9                                    139.2 s   \-                    138.8 s   \-

  10                                   134.4 d   7.84, d (7.3)         134.2 d   7.96, d (6.6)

  11                                   120.1 d   7.72, d (7.3)         119.8 d   7.84, d (6.6)

  11a                                  133.3 s   \-                    133.0 s   \-

  12                                   189.3 s   \-                    189.2 s   \-

  12a                                  116.6 s   \-                    116.4 s   \-

  12b                                  162.4 s   \-                    162.3 s   \-

  13                                   27.1 q    1.27, s               27.3 q    1.31, s

  Sugar A, β-[d]{.smallcaps}-olivose                                             

  1A                                   72.7 d    4.92, brd (11.4)      72.2 d    5.03, brd (9.1)

  2A                                   37.9 t    1.50, m2.38, m        37.3 t    1.56, m2.43, m

  3A                                   78.0 d    3.68, m               77.5 d    3.89, m

  4A                                   75.1 d    3.47, dd (9.3, 9.3)   75.3 d    3.46, dd (7.6, 7.8)

  5A                                   75.6 d    3.56, m               74.6 d    3.67, m

  6A                                   17.9 q    1.31, d (5.8)         17.6 q    1.26, d (5.6)

  Sugar B                                                                        

  1B                                   91.0 s    4.97, brs             90.5 d    6.06, brs

  2B                                   73.7 d    3.88, m               74.4 d    4.34, m

  3B                                   32.6 t    1.92, m1.96, m        35.9 d    2.54, m

  4B                                   64.1 d    4.12, m               171.4 s   \-

  5B                                   74.7 d    4.24, m               169.8 s   \-

  6B                                   11.5 q    1.26, d (6.9)         20.8 q    2.17, s
  ----------------------------------------------------------------------------------------------------

^a^ Residual signals of the solvent as a reference. ^b^ Measured in CD~3~OD. ^c^ Measured in acetone-d~6~.
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###### 

Cytotoxicity of **1**--**11** against MCF-7, MDA-MB-231, and BT-474 cells (IC~50~, μM).

  Compounds         Cell lines                  
  ----------------- ------------- ------------- -------------
  **1**             6.07 ± 0.09   7.72 ± 0.76   4.27 ± 2.09
  **2**             \>20          \>20          \>20
  **3**             \>20          \>20          \>20
  **4**             \>20          \>20          \>20
  **5**             7.58 ± 1.19   8.01 ± 0.55   6.46 ± 1.92
  **6**             \>20          \>20          \>20
  **7**             0.42 ± 0.03   0.35 ± 0.03   0.67 ± 0.09
  **8**             0.24 ± 0.01   0.16 ± 0.02   0.28 ± 0.09
  **9**             0.40 ± 0.01   0.38 ± 0.04   0.41 ± 0.15
  **10**            \>20          \>20          \>20
  **11**            \>20          \>20          \>20
  **Doxorubicin**   0.86 ± 0.64   1.30 ± 0.25   0.39 ± 0.06

[^1]: These authors contributed equally to this paper.
